Dupilumab Increases the Proportion of Patients With Fractional Exhaled Nitric Oxide Levels <20 ppb Over Time in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation: From Phase 3 Boreas

B52. EVIDENCE FOR THERAPEUTIC STRATEGIES IN COPD: FROM ESTABLISHED TO EMERGING（2024）

Cited 0|Views2

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined

Dupilumab Increases the Proportion of Patients With Fractional Exhaled Nitric Oxide Levels &lt;20 ppb Over Time in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation: From Phase 3 Boreas